Drug Trial Radar · NCT06948955
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Cogent Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2025
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no comparable or satisfactory alternative therapy options. The combination of bezuclastinib and sunitinib provides broad inhibition of all primary and secondary KIT mutations that commonly occur in GIST.
Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Interventions
BezuclastinibDrug
Drug: Bezuclastinib
SunitinibDrug
Drug: Sunitinib (locally sourced)
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona · Available
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Available
UCLA Department of Medicine- Hematology/Oncology
Los Angeles, California · Available
University of Colorado
Aurora, Colorado · Available
Smillow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut · Available
Mayo Clinic
Jacksonville, Florida · Available
Orlando Health
Orlando, Florida · Available
Northwestern Memorial Hospital
Chicago, Illinois · Available
The University of Chicago Medical Center
Chicago, Illinois · Available
Johns Hopkins University
Baltimore, Maryland · Available
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts · Available
Karmanos Cancer Institute
Detroit, Michigan · Available
Mayo Clinic
Rochester, Minnesota · Available
Roswell Park Cancer Institute
Buffalo, New York · Available
Memorial Sloan Kettering Cancer Center
New York, New York · Available
Cleveland Clinic Foundation
Cleveland, Ohio · Available
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Available
Taylor Cancer Research Center
Maumee, Ohio · Available
Oregon Health and Sciences University
Portland, Oregon · Available
Thomas Jefferson University
Philadelphia, Pennsylvania · Available
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Available
MD Anderson Cancer Center
Houston, Texas · Available
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Available
Shenandoah Oncology
Winchester, Virginia · Available
Shenandoah Oncology
Winchester, Virginia · Available
Northwest Medical Specialties
Tacoma, Washington · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.